![]() | |
Names | |
---|---|
IUPAC name
azane; 2-methylpyridine; platinum(2+); dichloride
| |
Identifiers | |
3D model (
JSmol)
|
|
ChemSpider | |
ECHA InfoCard | 100.205.233 |
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C6H10Cl2N2Pt | |
Molar mass | 376.14 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Picoplatin is a platinum-based antineoplastic agent in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid tumors. [1]
In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer. [2] However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer. [3] Hopes are now pinned on its use for metastatic colorectal cancer. [4]
![]() | |
Names | |
---|---|
IUPAC name
azane; 2-methylpyridine; platinum(2+); dichloride
| |
Identifiers | |
3D model (
JSmol)
|
|
ChemSpider | |
ECHA InfoCard | 100.205.233 |
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C6H10Cl2N2Pt | |
Molar mass | 376.14 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Picoplatin is a platinum-based antineoplastic agent in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid tumors. [1]
In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer. [2] However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer. [3] Hopes are now pinned on its use for metastatic colorectal cancer. [4]